Efficacy and safety of anti-Tumor Necrosis Factor-α biosimilars in Juvenile Idiopathic Arthritis - a systematic review and meta-analysis
Authors' conclusion
Biosimilars and originators of aTNF are similar in efficacy and safety in pediatric patients with JIA.
Study context
- Population
- Patients with Juvenile Idiopathic Arthritis (JIA) treated with anti-TNF-α biosimilars, studies published from inception to 30th August 20245 observational studies
- Comparison
- TNF biosimilars vs originators or placebo in JIA
- Outcome
- Efficacy (disease activity by JADAS) and safety of TNF biosimilars
Methodological detailsROBINS-I risk of bias assessment, descriptive synthesis, Risk of bias assessed as serious in all studies
- ROBINS-I risk of bias assessment
- Descriptive synthesis
- Risk of bias assessed as serious in all studies
Pooled result
As reported in the abstract
Disease activity (JADAS), head-to-head biosimilars vs originators
- All but one study showed no significant difference between biosimilars and originators in disease activity (Juvenile Arthritis Disease Activity Scores (JADAS))
- In two switching studies (originator to biosimilar), disease activity remained stable after switch until end of follow-up
- Risk of bias serious in all studies
Safety
| Outcome | OR (95% CI) | |
|---|---|---|
| Adverse events | 0.78 (0.52–1.17) | |
| 0.512Odds ratio (log scale) |
Original publication
Efficacy and safety of anti-Tumor Necrosis Factor-α biosimilars in Juvenile Idiopathic Arthritis - a systematic review and meta-analysis. Semin Arthritis Rheum. Published 16 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →